ArticleDiscover oncology2026
Significant efficacy of trastuzumab emtansine in HER2-positive relapsed mammary Paget's disease: a case report and literature review.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 58-year-old female patient was referred to our hospital due to a left chest wall relapse after a surgical excision 20 years ago. She received taxanes and trastuzumab regimen treatment for chest wall recurrence in 2019, but subsequently discontinued the treatment due to personal reasons. Her left chest wall was ruptured and oozed with pus when she came to our hospital. The tumor biopsy confirmed HER2 (human epidermal growth factor receptor 2) positive breast cancer metastasis, and she was diagnosed with mammary Paget’s disease (MPD). The skin symptoms regressed successfully with Trastuzumab Emtansine (T-DM1) treatment. This case suggests that the T-DM1 regimen is effective in relapsed MPD with HER2-positive and anti-HER2 targeted therapy should be considered as an option for the treatment of HER2-positive MPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.